Stat1 is de®cient or inactive in many types of human tumors whereas some tumors have activated Stat1. Whether Stat1 aects tumor growth and metastasis is unclear. In the present study, we used Stat1 knockout tumor cells to determine (1) whether Stat1 can regulate angiogenesis, growth, and metastasis of tumor cells; and (2) whether Stat1 is required for the inhibitory eect of IFN-b on the expression of angiogenic factor bFGF. Highly tumorigenic and metastatic RAD-105 tumor cells derived from a ®brosarcoma of a Stat1 knockout mouse were reconstituted with a Stat1 expression vector. The reconstitution of Stat1 suppressed the tumorigenicity and metastasis of RAD-105 cells in nude mice which correlated with a decreased microvessel density and decreased expression of proangiogenic molecules bFGF, MMP-2, and MMP-9 in vivo. Moreover, noncytotoxic concentrations of IFN-b signi®cantly inhibited the in vitro expression of bFGF in the Stat1-reconstituted cells but not in the Stat1-de®cient cells, which was consistent with decreased bFGF expression of Stat1-reconstituted tumors in vivo. Therefore, Stat1 is essential for IFNmediated inhibition of bFGF production, suggesting that tumor-intrinsic Stat1 is an important mediator for antiangiogenic signals, such as IFN. Collectively, these data demonstrate that Stat1 expressed by tumor cells is a negative regulator of tumor angiogenesis and, hence, tumor growth and metastasis.
Introduction
The biological activity of many cytokines and growth factors is mediated by activation of Stat (signal transducer and activator of transcription) family proteins. Recent studies have revealed that altered Stat3 and Stat5, but not Stat1, could contribute to oncogenesis (Bowman et al., 2000; Song and Grandis, 2000; Lin et al., 2000; Levy and Gilliland, 2000; Coer et al., 2000; Danial and Rothman, 2000) . Stat1 de®ciency has been found in some gastric adenocarcinomas (Abril et al., 1998) , T cell lymphomas , and melanomas (Wong et al., 1997; Pansky et al., 2000) . Expression of Stat1 has been shown to be associated with IFN-g-dependent immune response against chemically induced tumors in immunocompetent mice (Kaplan et al., 1998) . In contrast, constitutive activation of Stat1 has been reported in some tumors (Bowman et al., 2000) . In addition, Stat1 can be activated by a wide range of cytokines and growth factors, such as interferon (IFN), interleukin-6 (IL-6), IL-10, growth hormone, leukemia inhibitory factor (LIF), epidermal growth factor (EGF), and plateletderived growth factor (PDGF) (Larner et al., 1993; Ru-Jamison et al., 1993; Sadowski et al., 1993; Silvennoinen et al., 1993; Raz et al., 1994; Campbell et al., 1995) . These cytokines can either inhibit or promote proliferation of tumor cells, suggesting the association of Stat1 with tumor growth is complex. Thus, it is very important to determine the role of Stat1 in tumor growth and metastasis.
The progressive growth and metastasis of most tumors are angiogenesis-dependent. The extent of tumor angiogenesis is determined by the balance between the proangiogenic molecules and antiangiogenic molecules released by both tumor cells and surrounding host parenchymal cells and in®ltrating leukocytes (Folkman, 1992; Fidler and Ellis, 1994; Fidler, 1995) . The major positive angiogenic molecules include basic ®broblast growth factor (bFGF), vascular endothelial growth factor/vascular permeability factor (VEGF/VPF), and matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9) (Senger et al., 1983; Shing et al., 1985; Folkman and Klagsbrun, 1987; Leung et al., 1989; Fidler and Ellis, 1994) . A major negative regulatory molecule of angiogenesis is interferon, which has been shown to downregulate transcription and protein production of MMPs (Fabra et al., 1992; Qin et al., 1998) , bFGF (Singh et al., 1995) , and IL-8 (Oliveira et al., 1994) to inhibit endothelial cell migration (Brouty-Boye and Zetter, 1980) as well as induce the angiostatic factor IP-10 (Luster et al., 1985; Angiolillo et al., 1995; Arenberg et al., 1996) .
Stat1 activation has been demonstrated to be the main pathway for IFN-a, -b, and -g (Darnell, 1998).
The binding of IFN to the cell surface receptor leads to receptor clustering and transphosphorylation of receptor-associated Janus kinases (Jaks) (Darnell et al., 1994; Ihle and Kerr, 1995) . Jak-mediated phosphorylation activates Stat1 ; however, Stat1-independent pathways are also activated by IFN (Ramana et al., 2000 Gil et al., 2001 ) raising an interesting question as to whether Stat1 is required for the inhibitory eect of IFN-b on the expression of angiogenic factors, such as bFGF.
To better understand the function of Stat1 in tumor progression, we examined angiogenesis, tumor progression of murine ®brosarcoma RAD-105 cells derived from Stat1 knockout mice in nude mice with the eects in RAD-105 cells reconstituted with Stat1. The reconstitution of Stat1 suppressed the tumorigenicity and metastatic potential of RAD-105 cells in nude mice, which was correlated with a decreased microvessel density and decreased expression of multiple angiogenic molecules (bFGF, MMP-2 and MMP-9). Thus, suppression of tumor growth and metastasis by Stat1 can be mediated by downregulation of angiogenesis via mechanisms including inhibition the production of angiogenic molecules. Moreover, we found that Stat1-de®cient tumor cells do not respond to the IFNs inhibitory eect on bFGF production. Collectively, the data provide direct evidence that Stat1 is a negative regulator for tumor angiogenesis, growth, and metastasis.
Results

Restoration of functional Stat1 into Stat1 knockout fibrosarcoma cells by transfection of a Stat1 expression vector
To provide direct evidence that Stat1 plays a role in regulating tumor growth and metastasis, we utilized a Stat1-de®cient ®brosarcoma cell line established from a Stat1 knockout mouse To determine whether the decrease in bFGF protein resulted from inhibition of bFGF gene transcription, the above cell lines were incubated for 5 days in medium alone or medium containing 500 U/ml IFN-b. mRNA was isolated and analysed for bFGF-speci®c mRNA transcripts by Northern blot analysis ( Figure  4b ). IFN-b-treated RAD-105-ST cells expressed 50 ± 70% less bFGF mRNA than did untreated cells, whereas IFN-b did not reduce the bFGF mRNA level in control RAD-105-H cells. Moreover, the promoter activity of the bFGF gene in cells treated with IFN-b (500 U/ml) for 48 h was signi®cantly suppressed in /mouse) were injected s.c. into groups of nude mice (n=5). The s.c. tumors were harvested when they were about 5 mm in diameter and processed for immunohistochemical staining for vascular formation with an anti-CD-31 antibody. bFGF, MMP-2, and MMP-9 expression was determined by immunostaining with speci®c bFGF, anti-MMP2, and anti-MMP-9 antibodies. Phosphorylated Stat1 was detected by immunostaining with speci®c phospho Stat1 (Tyr 701) antibody. The image shown is a combined staining for nuclei (blue) and phosphorylated Stat 1 (red). Note that the decreased MVD in Stat1-reconstituted RAD-105 tumors correlated with a low level of bFGF, MMP-2, and MMP-9 expression. This is one representative experiment of three IFN-treated RAD-105-ST cells as compared to untreated cells, but not in control IFN-b-treated RAD-105 and RAD-105-H cells (Figure 4c ).
Loss of Stat1 transgene correlates with decreased tumorigenicity
In the ®nal set of experiments, tumor lesions formed in the lung of a nude mouse by Stat1-reconstituted cells (RAD-105-ST1) were isolated and established in culture. These cells did not express Stat1 as determined by Western blot analysis ( Figure 5 , insert) and were thus designated as RAD-105-ST1-R (revertent). The RAD-105-H, RAD-105-ST1, and RAD-105-ST1-R cells were injected s.c. into groups of nude mice. The revertant cells (that do not express Stat1) produced progressively growing tumors in nude mice, whereas the cells expressing Stat1 did not.
Discussion
In the present study, we provided direct evidence for the inhibitory role of Stat1 in regulation of tumor angiogenesis, growth, and metastasis. This conclusion is based on the results showing that enforced expression of Stat1 in Stat1-de®cient murine ®brosar-coma cells signi®cantly suppressed their tumorigenicity and metastatic potential in nude mice. The inhibition of tumor growth and metastasis correlated with decreased expression of the proangiogenic molecules bFGF, MMP-2 and MMP-9 and, hence, MVD in the tumors.
Since Stat1 is functional in signal transduction and transcription for many cytokines and especially for the IFNs (Durbin et al., 1996; Meraz et al., 1996) , we hypothesized that in the absence of Stat1, tumor cells may escape the negative regulatory signals for angiogenesis and invasion, e.g. IFN released by host cells (Sen and Lengyel, 1992; Pestka, 1997) . Indeed, in the present study, we found that Stat1-de®cient murine ®brosarcoma RAD-105 cells produce progressively growing tumors and many experiment lung metastases as compared with Stat1-reconstituted RAD-105 cells. Stat1 reconstituted cells had an in vitro growth rate similar to Stat1-de®cient cells in normal culture . Fire¯y and Renilla luciferase activities were quanti®ed using the dual-luciferase reporter assay system for calculating speci®c bFGF promoter activity. Per cent of luciferase activity was calculated relative to the luciferase activity of pRL-bFGF in untreated cells, which were given the reference value of 100%. This is one representative experiment of three. *P50.01
Stat1 in angiogenesis and metastasis S Huang et al medium that lacked Stat1-phosphorylation activators. Therefore, the discrepancy between the in vivo and in vitro growth of Stat1-expressing cells could have been due to the presence of Stat1-activating factors in the tumor microenvironment. The survival and growth of tumor cells are dependent on angiogenesis. In the absence of neovascularization, solid tumors cannot grow beyond 1 ± 2 mm in diameter (Folkman, 1992; Fidler, 1995) . One striking ®nding of this study was that Stat1-reconstituted RAD-105 cells produced small foci in the lungs (50.5 mm in diameter) in T cell-compromised nude mice. Indeed, the RAD-105, RAD-105-H, and RAD-105-ST tumors did not contain any CD4 + cells. All tumors had few CD8 + cells as revealed by immunohistochemistry (data not shown), suggesting that speci®c T cell immune response may not be the major mechanism for the antitumor activity of Stat1 in this study. Conversely, immunostaining with anti-CD-31 antibody revealed that MVD in subcutaneous tumors produced by Stat1-reconstituted RAD-105 cells was signi®cantly lower than that in subcutaneous tumors produced by RAD-105 or RAD-105-H cells, suggesting that the suppression of tumor growth by Stat1-reconstituted tumor cells was mainly due to inhibition of angiogenesis.
One of the cytokines that serves as an upstream signal for inhibition of angiogenesis by Stat1 activation may be IFN. Many types of host cells produce IFNs. IFN-a and IFN-g are mainly produced by leukocytes (Sen and Lengyel, 1992; Pestka, 1997) , whereas IFN-b is produced by ®broblasts and other cells including epithelial cells and macrophages (Sen and Lengyel, 1992; Pestka, 1997) . To determine whether Stat1-de®cient cells can circumvent the antiangiogenic eects of IFN, we examined whether Stat1 was required for downregulating bFGF production by IFN. Previous reports have demonstrated that IFNs can directly inhibit the proliferation of tumor cells in vitro (Balkwill and Oliver, 1977; Lin et al., 1986) . This antiproliferative eect is dependent on full activation of Stat1 by IFNs (Bromberg et al., 1996) ; however, the inhibition of the angiogenic molecule bFGF was not associated with the antiproliferative eects of IFNs because the concentration of IFN necessary to inhibit bFGF production was signi®cantly lower than that necessary to produce cytostasis (Singh et al., 1995) . Although IFN-g can produce cytostasis against human carcinoma cells, it does not inhibit bFGF transcription or production of the bFGF protein (Singh et al., 1995) . Moreover, the regulation of certain genes by IFNs could occur through Stat1-dependent or -independent pathways Ramana et al., 2000 Ramana et al., , 2001 . All above observations raised the question whether Stat1 is essential signaling component for the inhibition of expression of angiogenic molecules by IFN. We found that treatment with IFN-b led to the suppression of bFGF production only in Stat1-reconstituted RAD-105-ST cells but not in Stat1-de®cient RAD-105 and RAD-105-H cells. Consistent with a previous report (Singh et al., 1995) , the concentration of IFN-b required for suppression of bFGF production was much lower than that required for the inhibition of cell growth by IFN-b. Therefore, Stat1 reconstitution restores IFN-mediated suppression of bFGF, suggesting that the inhibitory eect required intact Stat1. Furthermore, the inhibition of the promoter activity of bFGF by IFN-b suggested that IFN-b regulates bFGF expression at least in part at the transcription level. Currently, it is not known whether the bFGF promoter contains Stat1 binding sites. The mechanism may parallel that for AP-1. The promoter of bFGF contains AP1-binding sites (Shibata et al., 1991) , and IFNinducible p202 protein binds to the AP-1 c-Jun and cFos protein and hence inhibits AP-1 activity (Min et al., 1996) . Stat1 activated by IFN-g can also inhibit AP1 activity by competition for binding of coactivator CBP/p300, which is essential for AP-1 activity in the macrophage (Horvai et al., 1997) . Whether IFN-bactivated Stat1 interacts with the bFGF promoter by either binding to the promoter directly or by modulating AP-1 activity indirectly is under investigation in our laboratory.
These results complement our previous ®ndings that host endogenous IFN-b is an angiogenesis inhibitor and that down-regulation of this endogenous inhibitor resulted in increased angiogenesis (Bielenberg et al., , 1999 . The loss of Stat1 in tumor cells render them insensitive to endogenous angiogenic inhibitory eects of IFN-b, resulting in augmented tumorassociated angiogenic activity hence enhanced tumorigenesis and metastatic potential. On the other hand, our ®nding that regulation of angiogenic molecule production by IFN is dependent on Stat1 also holds important clinical implications. The expression of Stat1 in certain metastatic melanoma and gastric adenocarcinoma cells is greatly depressed and correlates with unresponsiveness of these tumors to IFN-a (Wong et al., 1997; Abril et al., 1998; Pansky et al., 2000) ; therefore, diminished Stat1 expression could render tumor cells resistant to IFN antiangiogenic therapy (Dinney et al., 1998; Slaton et al., 1999) .
Although our data suggest that the main mechanism by which Stat1 inhibits tumor growth and metastasis in nude mice is by inhibiting angiogenesis, the involvement of Stat1 in the signal transduction pathway of other cytokines and growth factors is also possible. For example, it has been shown that the growth inhibition by EGF in several cell lines requires the activation of Stat1 (Bromberg et al., 1998) . The activation of the Stat1-signaling pathway by IFN-g and EGF can lead to expression of caspase 1 and apoptosis (Chin et al., 1997; Kumar et al., 1997) . Stat1 is required for ecient constitutive expression of the caspase Ice, CPP32, and Ich-1 in human ®broblasts (Kumar et al., 1997) . Stat1 also mediates cell growth arrest by inducing expression of the CDK inhibitor p21 (Chin et al., 1996) . Stat1 may also be involved in IFN-mediated immunomodulating eects (Kaplan et al., 1998) . For example, it has been shown that IFN-g has extrinsic tumor surveillance eects in immunocompetent mice, and those eects required an intact JAK-STAT signaling pathway (Kaplan et al., 1998) . The activation of Stat1, Stat3, and Stat5 in neoplasms can play opposite roles. Stat3 and Stat5 have been shown to promote oncogenesis. In contrast, Stat1 suppresses oncogenesis (Bowman et al., 2000; Song and Grandis, 2000; Lin et al., 2000; Levy and Gilliland, 2000; Coer et al., 2000; Danial and Rothman, 2000) . Our present data clearly agree with this conclusion and suggest a critical role of Stat1 in negative regulation of tumor growth and metastasis.
In conclusion, we have demonstrated that, Stat1, an important signal transducer, presumably activated by IFN produced in the tumor microenvironment, negatively regulates tumor-derived angiogenic factor production and neovascularization and, hence, tumor growth and metastasis. Tumor angiogenesis is determined by the imbalance between the expression proangiogenic and antiangiogenic factors in tumors. Our study suggests that aberrant expression of Stat1 may be an important part of the imbalance of proangiogenic and antiangiogenic forces and contributes to tumor progression. Therefore, Stat1 may be a potential target for antiangiogenic cancer therapy.
Materials and methods
Cell lines and reagents
Fibrosarcoma RAD-105 was established in Dr Robert D Schreiber's laboratory (Kaplan et al., 1998) . The cell line was maintained in 5% CO 2 and 95% air at 378C in minimal essential medium (MEM) supplemented with 10% fetal bovine serum (FBS), sodium pyruvate, nonessential amino acids, L-glutamine, and vitamin solution (Flow Laboratories, Rockville, MD, USA). All cultures were free of mycoplasma and pathogenic murine viruses. Murine recombinant IFN-b was obtained from Access Biomedical Co. (San Diego, CA, USA). Hygromycin (Sigma Chemical Co., St. Louis, MO, USA) was used at a ®nal concentration of 300 mg/ml. All reagents used for tissue culture were free of endotoxin as determined by the Limulus amebocyte lysate assay (sensitivity limit of 0.125 ng/ml) purchased from Associates of Cape Cod (Falmouth, MA, USA).
Animals
Male athymic BALB/c nude mice were purchased from the Animal Production Area of the National Cancer Institute, Frederick Cancer Research Facility (Frederick, MD, USA). The mice were housed in laminar¯ow cabinets under speci®c pathogen-free conditions and used at 8 weeks of age. Animals were maintained according to institutional regulations in facilities approved by the American Association for Accreditation of Laboratory Animal Care in accordance with current regulations and standards of the United States Department of Agriculture, Department of Health and Human Services, and National Institutes of Health.
Construction and transfection of Stat1 expression vectors
The pcDNA3.1/Hygro-Stat1 was generated by excising fulllength Stat1 from pcDNA3.Mu Stat1 plasmid (a generous gift from Dr Schreiber) with XhoI and subcloning it into the XhoI site of pcDNA3.1/Hygro vector (Invitrogen). For stable transfection, tumor cells were transfected using 15 ml of lipofectin reagent (Life Technologies, Inc., Gaithersburg, MD, USA) and 4 mg of pcDNA3.1/Hygro-Stat1 expression vector or control pcDNA3.1/Hygro vector according to the manufacturer's instructions. Cells were then selected with standard medium containing 300 mg/ml Hygromycin. Fourteen days later, hygromycin-resistant colonies were pooled. Three independent transfections of Stat1 expression vector were carried out in RAD-105 cells (RAD-ST1, ST2, ST3).
Western blot analysis
The soluble cytosolic protein was isolated and separated on 7.5% SDS ± PAGE by electrophoresis, and electrophoretically transferred onto Immobilon-P transfer membrane (Millipore). Stat1 was probed with a anti-Stat1 antibody (BD Transduction Laboratories, San Diego, CA, USA). Phosphorylation of Stat1 was detected by a phospho Stat1 (Tyr 701) antibody (New England Biolabs, Inc., Beverly, MA, USA). The probe proteins were detected with the Amersham ECL system according to the manufacturer's instructions. Equal loading of protein samples was monitored by hybridizing the same membrane with an anti b-actin antibody (Sigma) .
Tumorigenicity and metastasis
For all in vivo experiments, tumor cells were harvested by a 1-min treatment with 0.25% trypsin and 0.02% EDTA, and only single-cell suspensions of cells with a viability of 495% were used. To produce subcutaneous tumors, 1610 4 viable RAD-105 ®brosarcoma cells or Stat1 transfected cells suspended in 0.1 ml HBSS were injected into the subcutis of nude mice (n=5). Tumor incidence and size were monitored three times per week. Tumors exceeding 3 mm in 
Quantitation of microvessel density (MVD)
To examine the MVD, subcutaneous tumors produced in nude mice by control and Stat1-transfected cells were embedded in OCT compound and frozen, sectioned, ®xed, and stained with rat anti-mouse CD31/PECAM-1 antibodies (Pharmingen, San Diego, CA, USA) (Bielenberg et al., 1999) . Areas containing the highest number of capillaries and small venules were identi®ed by scanning tumor sections at low power (640). Images of 10 1006 ®elds per sample were digitized and stored for further analysis. The blood vessels were counted in each ®eld of each sample. The total area of tumors in each ®eld was determined with an Optimas software program (Bielenberg et al., 1999) . MVD was calculated as the mean number of blood vessels (CD31/ PECAM-1+cells) in a 1-mm 2 area of tumor.
Immunohistochemistry
Subcutaneous tumors harvested at autopsy were ®xed in formalin and embedded in paran. Tissue sections (5 mm) were processed for immunostaining using anti-bFGF (Sigma), anti-MMP-2 and anti-MMP-9 (Oncogene Research Products, Cambridge, MA, USA) as described (Bielenberg et al., 1999) . Negative controls consisted of tissue sections immunostained with nonspeci®c IgG. The slides were examined in a bright®eld microscope. A positive reaction was indicated by a reddish-brown precipitate in the cytoplasm and nucleus. Tumor sections were also examined for expression of phosphorylated Stat1. Speci®cally, the sections were immunostained with antibodies against phospho Stat1 (Tyr 701) (New England Biolabs, Inc.). Nuclei were stained with Hoechst dye (1 : 2000) in TBS for 2 min. The combined images are of blue nuclei and red phospho Stat1.
ELISA for bFGF protein
Cultures were frozen at 7708C and then thawed. Following cell lysis, the level of bFGF protein in tumor cells was determined by using a quantitative immunometric sandwich enzyme immunoassay (ELISA) kit (Quantikine bFGF ELISA kit, R&D Systems, Minneapolis, MN, USA). The concentration of bFGF of the samples was determined by comparing the optical density of samples to the standard curve (Singh et al., 1995) .
Northern blot analysis
Cellular mRNA was extracted from tumor cells by using the FastTrack mRNA isolation kit (Invitrogen Co., San Diego, CA, USA) and analysed as described (Singh et al., 1995) . The cDNA probes used in the analysis were a bovine bFGF (Singh et al., 1995) , and a human b-actin probe. The cDNA probes were labeled with 32 P-deoxycytidine triphosphate using a random labeling kit (Boehringer Mannheim Biochemicals, Indianapolis, IN, USA). bFGF mRNA expression was quantitated in the linear range by a PhosphorImager using the ImageQuant software program (Molecular Dynamics, Sunnyvale, CA, USA). Expression was calculated from the ratio between the areas of the bFGF-speci®c mRNA transcripts and the b-actin transcripts (Singh et al., 1995) .
Promoter reporters and dual luciferase assays
Luciferase reporters driven by a full-length bFGF promoter (pRL-bFGF) was used in this study. The pRL-bFGF was generated by subcloning the bFGF 5'-flanking region (nucleotide positions -1880 to +311) from pF2.1 CAT plasmid (44) into the XhoI site of a pRL-null reporter containing a full-length renilla luciferase gene (Promega, Madison, WI, USA). RAD-105, RAD-105-H, and RAD-105-ST cells (1610 5 /plate) growing in 10-cm tissue culture plates were transfected with 5 mg of pRL-bFGF reporter plasmid using the Lipofectin reagent (Life Technologies, Inc.). Normalization of transfection eciency was done by cotransfection with a pGL2-b-actin reporter containing a full-length ®re¯y luciferase gene under the control of a human b-actin promoter . The pGL2-bactin was generated by subcloning the b-actin promoter upstream of the ®re¯y luciferase gene of pGL2-basic plasmid (Promega). Twenty-four hours after transfection, the cells were split 1 : 10 into 6-well tissue culture plates and allowed to adhere overnight. The cells were then treated with 0 or 500 U/ml murine IFN-b in 0.5% FBS MEM for 48 h. The cells were harvested in passive lysis buer (Promega). Fire¯y luciferase and renilla luciferase activities were quanti®ed using the dual luciferase assay system (Promega). The per cent luciferase activity was calculated relative to the luciferase activity of pRL-bFGF in untreated cells, which were given the reference value of 100% as described .
Statistical analysis
The signi®cance of the in vitro results was determined by the Student's t-test (two-tailed); the signi®cance of the in vivo metastasis results was determined by the Mann ± Whitney U test.
